When the go-to hedge sells off with equities, investors should ask what they actually hold.
A 49.3 reading below every major forecast puts BHP, RIO, and commodity-linked names in the crosshairs at...
R2 is now Rivian’s top seller, and Q4 looks bigger. Here is why that matters more than...
Skyrizi and Rinvoq now dwarf Humira. Watch Q3 for the cleanest read yet.
TMUS's 34% EPS jump and raised guidance point beyond wireless.
Q3 results land this morning, and the margin line without last quarter's tariff refunds is what investors...
Three consecutive beat-and-fade quarters raise a real question: has the market stopped paying for 13% revenue growth...
A hawkish hold with possible dissents from Hammack, Kashkari and Logan sets up December as the real...
A court loss for Novo Nordisk clears Lilly's marketing runway into open enrollment — right as the...
With $6.1B due by end-2028 and a $3B Sandals deal, the question is whether guidance holds.